Lung neoplasm

Researchers are testing an experimental cell therapy called HS-IT101 in people with advanced non-small cell lung cancer. The treatment uses tumor-infiltrating lymphocytes (TILs), immune cells taken from the patient's own tumor, multiplied in the lab, and given back. Before receiv…

This trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…

This phase 2 trial tests whether three cycles of the immunotherapy drug cemiplimab can cure patients with stage I non-small cell lung cancer who cannot undergo surgery or radiation. Researchers will select patients likely to respond to immunotherapy and treat them with cemiplimab…

This phase II trial tests whether giving a combination of firmonertinib, anlotinib, and chemotherapy before surgery can shrink or eliminate tumors in people with resectable EGFR-mutant non-small cell lung cancer. The study enrolls adults with stage IIA-IIIB disease who have speci…

This trial is testing a surgical technique called septum-guided segmentectomy for people with early-stage (2-3 cm) non-small cell lung cancer. The surgery aims to remove only the diseased part of the lung, guided by natural anatomical landmarks, while preserving healthy tissue. T…

This phase II trial is testing whether a novel radiation technique called spatially fractionated radiotherapy (SFRT), which delivers alternating high and low doses inside the tumor, can work together with the immunotherapy drug tislelizumab and standard chemotherapy to shrink lar…

This trial is testing whether giving a combination of iruplaltinib and pemetrexed before surgery can shrink tumors in people with early-stage ALK-positive non-small cell lung cancer. The goal is to see if this pre-treatment improves the chance of removing all cancer during surger…

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…

This trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…

This phase 2 trial is testing whether a three-pronged approach—tumor ablation, immunotherapy (tislelizumab), and chemotherapy—can improve outcomes for people with stage II-IIIB non-small cell lung cancer that can be surgically removed. The goal is to see if this combination can e…

This trial investigates whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery can completely eliminate tumors in people with early-stage non-small cell lung cancer (tumors 2 to 3.9 cm). Participants will receive three cycles of the drug combinat…

This study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the tw…

Researchers are testing whether a doctor can remotely steer a robotic bronchoscope over a 5G network to freeze small lung tumors from inside the airway. The study enrolls about 15 adults with non-small cell lung cancer or controlled metastatic lung tumors, each no larger than 3 c…

Researchers are testing an experimental drug called 7MW3711 against the standard chemotherapy docetaxel in people with locally advanced or metastatic squamous non-small cell lung cancer. All participants have already received platinum-based chemotherapy and immunotherapy, and the…

This phase III trial will enroll 854 Hispanic adults who smoke and want to quit. Participants will use the iCanQuit smartphone app, which teaches skills to manage cravings and prevent relapse. Half will also receive nicotine replacement therapy (gum, patch, or lozenge) to ease wi…

Researchers are testing whether adding the experimental drug RC148 to platinum-based chemotherapy helps people with advanced non-squamous non-small cell lung cancer live longer without their disease worsening, compared with tislelizumab plus the same chemotherapy. The trial enrol…

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

Researchers are testing whether giving targeted therapy before and after surgery helps people with stage III non-small cell lung cancer that has specific rare gene changes. The study includes 190 adults whose tumors have alterations in genes like EGFR, ALK, ROS1, MET, RET, or KRA…

Researchers are running a phase 1 trial of SHR-4595, an experimental injectable drug, in adults with advanced solid tumors that have not responded to standard treatments. The study checks how safe and tolerable the drug is, how the body processes it, and what dose might work best…

This early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…

Researchers are testing whether combining BL-B01D1, an experimental antibody-drug conjugate, with glecirasib, a targeted KRAS G12C inhibitor, can shrink tumors in adults with locally advanced or metastatic non-small cell lung cancer that carries a KRAS G12C mutation. The phase 2 …

Researchers are testing whether a shared checklist used during lung cancer surgery helps surgeons achieve cleaner, more complete tumor removal. The trial enrolls adults with early-stage non-small cell lung cancer who are scheduled for surgery. Half the participating hospitals use…

Researchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

Researchers are testing whether adding the immunotherapy adebrelimab to HS-20093 (risvutatug rezetecan) works better than HS-20093 alone in adults with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated and has no actionable gene changes.…

Researchers are testing whether adding the experimental oral drug HS-10370 to platinum-based chemotherapy, with or without the immunotherapy adebrelimab, works better than tislelizumab plus chemotherapy. The trial enrolls about 448 adults with previously untreated, locally advanc…

Researchers are testing whether adding focused radiation to the few remaining cancer spots helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their disease getting worse. Participants first receive a third-generation EGFR-targeted drug plus plat…

Researchers are testing whether an experimental drug called telisotuzumab adizutecan works better than standard chemotherapy for people with non-squamous non-small cell lung cancer that has grown after earlier treatment. The trial enrolls about 660 participants whose tumors are E…

This trial tests an experimental drug called TUB-040 in adults with advanced non-small cell lung cancer that cannot be removed with surgery or has spread. TUB-040 is designed to attach to a protein on cancer cells and deliver a toxic payload directly to the tumor, potentially kil…

Researchers are studying the safety of selpercatinib, an oral drug, in people in India with advanced cancers that have changes in the RET gene. The trial includes adults with RET fusion-positive non-small cell lung cancer and adults and children aged 12 and older with RET-mutant …

Researchers are testing a combination of paclitaxel polymeric micelles and ivonescimab in adults with small cell lung cancer that has returned or stopped responding after platinum-based chemotherapy and anti-PD-1/PD-L1 therapy. The phase 2 trial aims to see how many participants'…

Researchers are testing whether giving toripalimab plus sacituzumab tirumotecan before surgery helps people with resectable non-small cell lung cancer. The trial enrolls about 30 adults with stage II to IIIB disease that has not been treated and lacks certain driver mutations. Pa…

Researchers are comparing an experimental oral drug called JYP0322 with crizotinib in adults who have not yet received treatment for ROS1-positive locally advanced or metastatic non-small cell lung cancer. The phase III trial aims to see which drug keeps cancer from worsening lon…

Researchers are testing whether adding stereotactic radiation to two drugs, envafolimab and endostar, helps people with stage IV non-small cell lung cancer. Participants have tumors without common EGFR, ALK, or ROS1 mutations and have not received prior systemic treatment. Everyo…

This study tests whether giving high-precision radiation (SBRT) to the main tumor and nearby lymph nodes, along with standard chemotherapy, can better control stage III non-small cell lung cancer. The trial will enroll 20 adults whose tumors are less than 6 cm and who have not sp…

This early-phase study tests a new cancer vaccine (EVM14) combined with an immunotherapy drug (ivonescimab) in 13 people with advanced squamous non-small cell lung cancer that has not been treated before. The main goals are to check safety and find the right dose, while also look…

Researchers are testing an experimental antibody called 3SC009 in adults with advanced or metastatic solid tumors that have not responded to other treatments. The drug is a bispecific antibody, meaning it binds to two different targets on cancer cells, CD47 and EpCAM. The trial h…

This trial tests a device that uses pulsed electric fields to destroy lung tumors. It is for people with early-stage non-small cell lung cancer or lung metastases that cannot be removed with surgery or treated with radiotherapy. Participants receive the ablation under general ane…

Researchers are testing a new drug called TS-104 in adults with advanced solid tumors, including lung, head and neck, ovarian, endometrial, esophageal, and gastric cancers. TS-104 is a peptide drug conjugate: it uses a targeting peptide to carry the chemotherapy drug MMAE directl…

People newly diagnosed with breast, colorectal, lung, or prostate cancer often also manage other long-term conditions and take multiple medications. This pilot study tests whether a pharmacist-led medication review plus the Medisafe mobile app helps them stick to those regimens. …

Researchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …

This early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…

This study tests whether a very thin freezing needle can safely biopsy and destroy suspicious lung nodules in one procedure. About 30 adults with small lung nodules who are not candidates for or decline surgery will undergo the combined approach under CT guidance. Researchers wil…

This early-phase trial tests an oral drug called R01 in people with advanced squamous cell lung cancer, gastric cancer, or esophageal cancer that has progressed after standard treatment. The study aims to find the safest dose and check whether R01 can shrink tumors. Participants …

This early-stage trial tests an experimental drug called STRO-006 in adults with advanced solid tumors, including head and neck, lung, esophageal, gastric, colorectal, endometrial, bladder, and breast cancers that have not responded to standard treatments. The study has three par…

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This Phase 2 trial tests whether adding lurbinectedin to paclitaxel works better than paclitaxel alone for people with advanced small cell lung cancer that has returned after first treatment. About 69 adults will be randomly assigned to one of two groups. The study measures how m…

This phase 2 trial tests whether zipalertinib, an oral drug that targets cancer cells with atypical EGFR mutations, can eliminate remaining cancer cells in people with early-stage non-small cell lung cancer. Participants who have completed standard treatment and show signs of min…

This trial tests whether a coordinated care pathway, involving oncologists, geriatricians, pharmacists, and pharmacologists, can reduce severe side effects in adults over 70 with certain cancers who are starting oral therapy. Participants receive extra monitoring, including blood…

This phase III trial compares an experimental combination of two drugs, QLC5508 and QL2107, against the current standard treatment (tislelizumab plus chemotherapy) as a first-line therapy for people with extensive-stage small cell lung cancer. The study enrolls adults who have no…

This phase 2 trial tests whether combining an experimental drug called SHR-7787 with the immunotherapy adebrelimab can help people with limited-stage small cell lung cancer. The study enrolls adults aged 18 to 75 whose cancer has not progressed after standard chemotherapy and rad…

This early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…

This trial tests whether a wireless wearable monitor (chest patch or wristband) plus a smartphone-based rehab program can help people recover lung function after surgery for non-small cell lung cancer. Participants who have had curative-intent surgery will either receive standard…

This phase 1 trial tests whether combining an experimental oral drug, JIN-A02, with an existing intravenous drug, amivantamab, is safe and can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer that has progressed after treatment with a third-generation …

This trial tests a cell therapy called DC-CTL, made from a patient's own immune cells, combined with standard anti-tumor treatment. The goal is to see if this approach is safe and may help control solid tumors such as colorectal, esophageal, lung, liver, and breast cancer. About …

This study tests whether adding a cancer vaccine (CIMAVAX-EGF) to standard targeted drugs (sotorasib or adagrasib) can help control advanced lung cancer with a KRAS G12C mutation. About 29 adults with stage III or IV non-small cell lung cancer will receive the combination. The go…

This first-in-human trial tests an experimental drug called BD200 in adults with advanced solid tumors that have not responded to standard treatments. BD200 is designed to latch onto two proteins, Trop-2 and Nectin-4, found on many cancer cells, potentially delivering a toxic pay…

This trial tests whether a digital rehabilitation program, combined with wireless wearable monitors, can help people recover faster between two planned lung cancer surgeries. Participants with multiple primary non-small cell lung cancer will be randomly assigned to either standar…

This trial tests a type of radiation called brain-avoidant proton craniospinal irradiation (BRAVO-pCSI) in people with leptomeningeal metastases, a condition where cancer spreads to the fluid and lining around the brain and spinal cord. The study includes adults with breast cance…

This early-phase trial tests whether a special MRI scan using hyperpolarized xenon gas can help doctors plan radiation treatment for non-small cell lung cancer. The goal is to deliver enough radiation to the tumor while avoiding healthy lung tissue, which could reduce side effect…

This Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread…

This phase 3 trial tests whether the experimental drug ZL-1310, when combined with an immunotherapy drug, can help people with extensive-stage small cell lung cancer live longer than those receiving standard chemotherapy plus immunotherapy. The study enrolls about 530 adults who …

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This trial tests a new approach to pulmonary rehabilitation, a standard programme of exercise and education for people with chronic lung disease. The twist is that informal carers, often family members, join the education and support sessions. The goal is to see if this carer-inc…

This phase 1/2 trial tests an investigational drug called HY07121, given as a subcutaneous injection, in adults with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study has two parts: the first finds a safe dos…

This phase II trial tests whether combining the antibody-drug conjugate sacituzumab tirumotecan (SKB264) with brain radiotherapy can control brain tumors in people with advanced EGFR-mutant non-small cell lung cancer. Participants have brain metastases that progressed after first…

This trial tests whether a ventilation strategy based on mechanical power—a measure of energy delivered to the lungs—can reduce postoperative pulmonary complications like pneumonia and collapsed lungs in adults undergoing lung resection surgery. Participants are randomly assigned…

This early-phase trial is testing an investigational drug called FL115 in adults with advanced solid tumours that have progressed after standard therapy or for whom no standard treatment exists. FL115 is designed to stimulate the immune system's natural killer cells and T cells t…

This trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy that targets PD-1 and VEGF, works better than standard chemotherapy combined with the same immunotherapy for people with advanced squamous non-small cell lung cancer. About 200 adults with th…

This early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standar…

This study tests whether adding a new drug, obrixtamig, to standard chemotherapy can help people with a rare and aggressive lung cancer called large-cell neuroendocrine carcinoma (LCNEC). The trial will include 75 adults with advanced LCNEC that cannot be cured by surgery. Resear…

This early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…

This early study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced lung and colorectal cancers. About 20 adults will receive NK cell infusions alongside their usual drugs. The main goal is to check for side effec…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This trial is investigating whether a new combination of drugs—BL-B01D1 plus a PD-1/VEGF bispecific antibody—can work better than the current standard treatment (tislelizumab plus chemotherapy) for people with locally advanced or metastatic non-squamous non-small cell lung cancer…

This early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …

This trial tests whether a structured exercise program can strengthen the immune system's attack on non-small cell lung cancer. Patients receiving chemo-immunotherapy before surgery will either follow an exercise plan with a stationary bike or receive standard recommendations. Th…

This trial investigates whether specially engineered T cells can safely target and fight lung cancer. Participants have advanced or relapsed lung cancer and receive a single infusion of their own T cells that have been trained to recognize cancer-specific markers. The study aims …

This phase 3 trial compares two surgical approaches for early-stage non-small cell lung cancer with small (≤2 cm), solid-dominant tumors located deep within the lung. One group receives segmentectomy, which removes only the affected segment of the lung, while the other receives l…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This phase II trial is testing whether combining two targeted drugs—andamertinib and anlotinib—can help people with advanced non-small cell lung cancer whose tumors have grown despite prior treatment with a third-generation EGFR inhibitor. The study enrolls adults with locally ad…

This early-stage trial is testing whether infusions of natural killer (NK) cells—a type of immune cell from a healthy donor—can safely help people with advanced solid tumors that have not responded to standard treatments. The study enrolls about nine adults aged 18 to 75 and uses…

This study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…

This phase 3 trial tests whether adding an experimental drug called izalontamab brengitecan to the standard targeted therapy osimertinib works better than osimertinib alone or with chemotherapy for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior…

This phase II trial is testing whether combining trastuzumab rezetecan, a targeted antibody-drug therapy, with radiotherapy can help people with HER2-mutated advanced non-small cell lung cancer whose disease has started to grow again after initial treatment. The study will enroll…

This trial tests whether tirzepatide, a medication used for weight management, can reduce the rapid weight gain and metabolic changes caused by lorlatinib, a targeted therapy for ALK-positive non-small cell lung cancer. Adults already taking lorlatinib will receive weekly tirzepa…

This phase II trial is testing whether giving the chemotherapy drug thiotepa directly into the spinal fluid—via a small device called an Ommaya reservoir—can help control cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases) in people with …

This early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…

This trial is testing whether combining two drugs—an immunotherapy called adebrelimab and a targeted therapy called trastuzumab rezetecan—can shrink tumors in people with stage III HER2-positive lung cancer that cannot be removed surgically. Participants receive several cycles of…

This phase II trial is testing whether adding a type of precise radiation called stereotactic body radiation therapy (SBRT) to standard immunotherapy can help people with stage IV cancers, including head and neck, lung, cervical, esophageal, and gastric cancers. Participants will…

This trial is testing two different radiation schedules for people with peripheral lung cancer or a single lung metastasis. One group receives the standard five-session treatment, while the other gets an experimental three-session approach. The goal is to see if the shorter sched…

This trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to …

This study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tri…

This study tests whether giving a dye called Cytalux a few days before surgery works as well as giving it closer to the operation. The dye makes tumors glow under a special light, helping surgeons remove them more completely. About 106 adults with suspected lung cancer or confirm…

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…

This trial tests whether combining an EGFR-targeted pill (EGFR-TKI) with an antibody-drug conjugate (trastuzumab rezetecan) can shrink tumors in people with advanced non-small cell lung cancer that has both an EGFR mutation and HER2 alterations. Participants receive the combinati…

This pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surger…

This study tests whether precisely targeted radiation (SBRT) can stop or slow the growth of a few resistant spots in metastatic lung cancer patients who are already on targeted therapy (TKI). About 60 adults with EGFR or ALK mutations will receive radiation to those spots, and do…

This trial is testing whether a blood test that detects cancer DNA can guide the use of durvalumab, an immunotherapy, after standard chemoradiotherapy in patients with stage III lung cancer that cannot be removed by surgery. The goal is to see if giving durvalumab only to patient…

This study tests whether a fecal microbiota transplant (FMT) — transferring healthy gut bacteria from a donor — can help restore the immune system's ability to fight advanced non-small cell lung cancer in 15 patients whose disease worsened after prior immunotherapy. Participants …

This phase 3 trial is testing whether an investigational drug called ABBV-1480, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced or metastatic squamous non-small cell lung cancer. Particip…

This trial is testing whether an experimental oral drug, HS-10504, can slow the progression of advanced non-small cell lung cancer in people whose tumors carry a specific EGFR C797S mutation and have already failed prior EGFR inhibitor therapy. Participants will be randomly assig…

This trial is testing an experimental drug called AMT-116 in people with advanced or metastatic non-squamous non-small cell lung cancer that has worsened after standard treatments. The study has two parts: the first compares two different doses of AMT-116 to see which works bette…

This early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…

This phase 2 trial tests whether the immunotherapy drug cemiplimab can be used alone before surgery for certain patients with early-stage non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if some patients can safely skip chemotherapy and its harsh side ef…

This trial is testing whether combining two targeted therapies—lorlatinib and sacituzumab tirumotecan—can better control advanced ALK-positive non-small cell lung cancer when used as the first treatment. The study involves about 153 adults with locally advanced or metastatic dise…

This trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…

This phase 2 trial is testing a novel combination for people with metastatic pancreatic cancer that has progressed after standard first-line chemotherapy. The approach combines a device that alternately freezes and heats the tumor (multimodal thermal therapy) with a personalized …

This phase II trial is testing whether combining an experimental drug called ALK201 with an existing immunotherapy, ivonescimab, can help people with advanced squamous non-small cell lung cancer. The study includes adults whose tumors have a specific marker (FGFR2b) and who have …

This trial tests whether a minimally invasive procedure called bronchoscopic microwave ablation can be as effective as surgery for early-stage lung cancer (stage IA). The procedure uses a bronchoscope to guide a needle to the tumor and destroy it with heat, potentially preserving…

This trial is testing an experimental drug called DS-3939a in adults with advanced solid tumors, including a type of lung cancer. The study has two parts: the first checks safety and the best dose, and the second looks at whether the drug, alone or with other cancer treatments, c…

This trial is testing whether giving radiotherapy to the main lung tumour, in addition to standard chemotherapy or immunotherapy, can reduce cancer spread and help people with metastatic non-small-cell lung cancer live longer. Around 420 adults with newly diagnosed stage IV lung …

This trial tests whether MRI-guided stereotactic body radiotherapy (SBRT) can safely treat ultra-central lung tumors—growths located near the windpipe and major airways. Using an MR-LINAC machine, doctors can adjust the radiation beam in real time as the patient breathes, potenti…

This early-stage trial tests whether an experimental drug called TLN-499, combined with the approved cancer drug venetoclax, is safe and tolerable for people with certain advanced solid tumors that have stopped responding to standard treatments. The study includes adults with sma…

This trial is testing a combination of three drugs—benmelstobart, anlotinib, and etoposide—as a first treatment for elderly patients (65 and older) or those too frail for standard intensive chemotherapy. The goal is to see if this platinum-free regimen can control the cancer and …

This early-phase trial is testing an experimental antibody-drug conjugate called MC002 in adults with advanced solid tumors, such as esophageal or lung cancer, that have progressed after standard treatments. MC002 is designed to target a protein found on cancer cells and deliver …

This trial compares two treatments for early-stage lung cancer in patients who cannot have surgery: microwave ablation delivered through a bronchoscope versus standard stereotactic body radiotherapy. The goal is to see which approach better controls the tumor over two years, with…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…

This study tests a new treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. It combines low-dose radiation to the chest with an immunotherapy drug (adebrelimab) and chemotherapy, followed by maintenance immunotherapy for up to t…

This phase 3 trial investigates whether adding platinum-based chemotherapy to the immunotherapy drug tislelizumab helps people with a specific type of advanced lung cancer live longer without the disease worsening. Participants have non-small cell lung cancer that has spread, sho…

This study tests whether a blood test can identify people with advanced lung cancer who can be treated with immunotherapy alone instead of chemotherapy plus immunotherapy. The trial enrolls 275 adults with high PD-L1 levels and a low inflammation blood score. The goal is to see i…

This early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…

This trial investigates whether combining two drugs—JS212 (given by IV) and JS111 (taken orally)—can safely and effectively shrink tumors in people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 20 participants who have not had prior treatment f…

This phase 2 trial tests whether adding an experimental drug called ABSK043 to the standard targeted therapy osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutated, PD-L1 positive). The study enrolls adults whose cancer has spread or cannot be surg…

This trial investigates a personalized approach for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior treatment. Participants first take the targeted pill befotertinib for three weeks, then a blood test checks for minimal residual disease (MRD). T…

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This phase II trial investigates whether combining the immunotherapy adebelizumab with other anti-tumor drugs, given before and after surgery, can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls adults aged 18-70 with stage II or IIIA dis…

This study tests an experimental drug called HSK41959, taken as a tablet, in combination with standard cancer treatments for people with advanced solid tumors that lack a gene called MTAP. The trial includes patients with non-small cell lung cancer, pancreatic cancer, and other a…

This phase 2 trial tests whether combining the immunotherapy drug toripalimab with a specific chemotherapy regimen can shrink tumors in people with advanced small cell lung cancer that has progressed after prior treatments. Participants receive toripalimab plus a rotating schedul…

This phase 2 trial is testing whether giving platinum-based chemotherapy (carboplatin and etoposide) together with the immunotherapy tarlatamab can help patients with advanced small-cell lung cancer whose disease has worsened while on tarlatamab alone. The study enrolls about 54 …

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …

This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…

This trial tests a combination of two drugs—tislelizumab and SYS6010—in people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after immunotherapy. Tislelizumab is an approved immunotherapy, and SYS6010 is an experimental drug that targets EGFR on can…

This study tests a new drug called XTX501 in people with metastatic non-small cell lung cancer (NSCLC) or other advanced solid tumors. The goal is to see if the drug is safe and can shrink tumors. Participants receive XTX501 alone, and researchers monitor side effects and how wel…

This study looks at how well third-generation EGFR-targeted drugs work as follow-up treatment after surgery for people with early-stage non-small cell lung cancer that has certain high-risk features. Researchers will observe about 500 patients in China who have EGFR mutations and…

This study tests a personalized cancer vaccine, made specifically for each patient, to see if it is safe and can help prevent non-small cell lung cancer from coming back after surgery. The vaccine is given alone or together with an immunotherapy drug called toripalimab. The trial…

This study investigates a drug called sacituzumab govitecan, which targets the TROP2 protein, in people with advanced non-small cell lung cancer that has stopped responding to standard EGFR-targeted treatments. Researchers are also comparing two types of PET/CT scans—one standard…

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This study tests whether recakimab, an injectable drug that lowers cholesterol, can safely reduce high cholesterol caused by the lung cancer medication lorlatinib. The trial enrolls about 29 adults with advanced ALK-positive non-small cell lung cancer who developed high cholester…

This pilot study tests whether an inhaled drug called cromolyn sodium, already used for asthma, is safe and feasible for people with locally advanced lung cancer. The drug works by calming mast cells, which may play a role in tumor growth and treatment resistance. About 5 to 10 p…

This study tests whether adding a Chinese herbal formula (Xuanyin Ning) to a standard cancer drug (bevacizumab) can better control malignant pleural effusion—fluid buildup in the chest caused by advanced lung cancer. About 308 participants will receive either the herbal formula o…

This study looks at the best way to manage high cholesterol caused by the targeted therapy lorlatinib in people with advanced ALK-positive non-small cell lung cancer. Some participants receive standard cholesterol-lowering drugs, while others get a more intensive combination. The…

This early-stage trial tests a new cell therapy called GK01 for people with advanced lung cancer who have not responded to standard treatments. The therapy uses a patient's own immune cells (T cells) that are specially prepared to attack the cancer. The main goal is to check safe…

This clinical trial compares a new three-drug combination (SYHX2011, carboplatin, and enlonstobart) against the standard three-drug regimen (nab-paclitaxel, carboplatin, and tislelizumab) as a first treatment for people with advanced squamous non-small cell lung cancer. The study…

This phase II trial tests a special type of radiation called lattice radiation therapy (LRT) combined with standard chemoimmunotherapy for people with stage III lung cancer that did not shrink enough after initial treatment. The LRT delivers high-dose radiation to specific spots …

This phase 4 trial tests whether combining two oral drugs—ensartinib and anlotinib—can shrink tumors or slow disease in people with ALK-positive non-small cell lung cancer that has become resistant to lorlatinib. About 80 adults with advanced (stage IIIB-IV) cancer will receive t…

This Phase 3 trial tests whether adding the experimental drug SYS6010 to standard immunotherapy can better prevent lung cancer from returning after surgery. About 570 adults with stage II-IIIB non-small cell lung cancer who did not respond well to pre-surgery treatment will be ra…

This phase 2 trial tests the drug trastuzumab deruxtecan (T-DXd) in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has high levels of the HER2 protein. Participants receive T-DXd by IV every three weeks. The study measures how long the cancer stays und…

This phase 1 trial tests a radioactive drug called 211At-MABG in 16 adults with advanced neuroendocrine cancers, including pheochromocytoma and paraganglioma. The drug delivers radiation directly to cancer cells that show up on a special scan. The main goal is to see if the treat…

This Phase 2 trial is testing a drug called firmonertinib for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study uses a blood test (ctDNA) to decide if treatment should be adjusted over time. About 154 participants will receiv…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-phase study tests an inhaled mRNA immunotherapy for adults with advanced lung cancer or solid tumors that have spread to the lungs. The treatment is given as a dry powder through an inhaler. The main goal is to check safety and find the best dose, with 60 participants …

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This early-phase study tests an oral drug called SNH-118110 in 240 adults with advanced solid tumors that have a specific genetic change (RET). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have tried other treatm…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study tests a new drug combination (SYS6010 plus enlonstobart) against the usual immunotherapy with chemotherapy for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). About 500 adults aged 18-75 who have not had prior treatment for their…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This Phase 2 trial tests whether adding two drugs (benmelstobart and anlotinib) to standard chemotherapy before chemoradiation helps people with stage III lung cancer that cannot be removed by surgery. 152 participants will be randomly assigned to receive either the new induction…

This study tests a combination of two drugs, QL1706 and anlotinib, for people with advanced small cell lung cancer who have already tried at least two prior treatments. The goal is to see if the combination helps control the cancer and extends survival. About 120 adults aged 18 t…

This study tests whether giving a Pfizer-BioNTech COVID-19 mRNA vaccine before standard immunotherapy (pembrolizumab) and chemotherapy can improve outcomes for people with stage 4 non-small cell lung cancer. Researchers will enroll 500 adults to see if the vaccine helps the immun…

This phase 2 trial tests whether combining two drugs, lomustine and anlotinib, can shrink tumors or slow disease in people with extensive-stage small cell lung cancer that has not responded to at least two prior treatments. About 46 participants will receive the drug combination …

This trial tests whether an intelligent breathing exercise device helps people recover lung function after surgery for non-small cell lung cancer. Participants use the device for breathing exercises twice daily for 30 days after surgery, while a comparison group receives standard…

This pilot study tests whether an inhaled drug called AER101 can reduce glycolysis—the process cancer cells use to break down sugar for energy—in early-stage non-small cell lung cancer. Participants inhale the drug three times daily for two weeks before their scheduled surgery. T…

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests whether adding tarlatamab to durvalumab after standard chemotherapy and radiation can delay cancer return and extend life in people with limited-stage small cell lung cancer. Tarlatamab works by helping immune cells recognize and attack cancer cells. About 430 pa…

This phase 2 trial tests two different immunotherapy drug combinations (durvalumab with monalizumab or oleclumab) followed by personalized radiation for people with advanced non-small cell lung cancer that has a high PD-L1 score. The goal is to see which combination works better …

This Phase II trial tests a combination of two drugs, trastuzumab rezetecan and ivonescimab, in 30 people with advanced non-small cell lung cancer that has HER2 gene abnormalities. The goal is to see if the combo can control the cancer and delay progression. Participants must hav…

This early-phase study tests two drugs together—navlimetostat and pumitamig—in people with advanced non-small cell lung cancer that has a specific genetic change (MTAP-deficient). The main goal is to find a safe dose and see if the combination helps shrink tumors. About 17 adults…

This study tests a new combination of two drugs (becotatug vedotin and pucotenlimab), with or without radiation, as a first treatment for people with advanced non-small cell lung cancer that has a specific protein (EGFR) on its surface. About 39 participants will receive the drug…

This phase 2 trial tests whether adding intermittent hypoxic training (IHT) – short sessions of breathing low-oxygen air – to standard chemo-immunotherapy can improve outcomes for people with stage II-IIIA lung squamous cell carcinoma. About 60 participants will receive either st…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This study tests whether taking only a few lymph node samples (selective sampling) works as well as removing all nearby lymph nodes (systematic dissection) in people with stage IIA-IIIB non-small cell lung cancer. All participants will first receive chemotherapy combined with imm…

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This phase II trial is testing whether the targeted therapy firmonertinib, taken as a pill for 8 to 16 weeks before surgery, can shrink tumors in people with stage II-IIIB EGFR-mutated lung adenocarcinoma. About 60 participants will receive the drug and then undergo surgery to re…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This phase II trial tests an immunotherapy drug called SHR-1701 combined with chemotherapy and radiation for people with unresectable stage III non-small cell lung cancer. The study will enroll 84 participants and compare giving SHR-1701 before or after standard chemoradiation. T…

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This study tests whether adding a special type of radiation (SF-SBRT) to the usual combination of immunotherapy (toripalimab) and chemotherapy helps people with stage II-III non-small cell lung cancer live longer without the cancer coming back. About 200 participants will be rand…

This study tests a new drug combination (IBI3005) in about 282 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check safety and see if the treatment shrinks tumors. Participants will be closely monitored for side effects a…

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This study tests a new drug called SCTB41 combined with the chemotherapy docetaxel in 90 people with advanced non-small cell lung cancer that has worsened after prior treatment. The goal is to see if the combination is safe and works better than docetaxel alone. Participants will…

This study tests a new drug called ALK202 combined with other medicines for people with advanced non-small cell lung cancer. The trial will include 252 participants and aims to see if the combinations are safe and can shrink tumors. It is divided into two phases: first to find th…

This Phase 3 trial tests a new drug called HRS-7058 against other KRAS G12C inhibitors in 450 adults with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has stopped responding to standard treatments. The study compares how well HRS-70…

This study tests whether giving sintilimab (an immunotherapy drug) together with chemotherapy can shrink advanced stage IIIC lung cancer enough to allow surgery. About 33 adults with previously untreated, unresectable non-small cell lung cancer will receive four cycles of the com…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This study tests a new approach for lung cancer patients who are at high risk of incomplete tumor freezing during cryoablation. Before the freezing procedure, doctors will block small blood vessels near the tumor using a temporary, absorbable material. The goal is to make the fre…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This study tests an oral chemotherapy (paclitaxel) combined with immunotherapy given before surgery in patients aged 70-85 with non-small cell lung cancer. The goal is to see if this approach can shrink tumors enough to improve surgery outcomes and long-term survival. About 75 pa…

This early-stage study tests a new treatment called DCTY1102 for people with advanced cancers (like pancreatic, colorectal, or lung cancer) that have a specific genetic change (KRAS/NRAS G12D mutation) and a certain immune type (HLA-A*11:01). The treatment uses the patient's own …

This Phase 3 trial tests whether adding an experimental drug called SYS6010 to the standard treatment osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) live longer without their cancer getting worse. About 680 participants will be random…

This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This study tests whether adding alpha lipoic acid (a strong antioxidant) to standard chemotherapy helps people with advanced non-small cell lung cancer. About 60 adults with stage III or IV lung cancer will take 600 mg of alpha lipoic acid daily alongside their chemo. Researchers…

This phase 2 trial tests whether fecal transplants from immunotherapy responders can improve outcomes in stage II-III non-small cell lung cancer. 68 patients will receive either standard treatment (Durvalumab + chemotherapy) or the same plus fecal transplant capsules. The main go…

This study tests whether a special omega-3-enriched nutritional drink can improve nutrition in people with advanced lung or colorectal cancer who are at risk of malnutrition. About 118 participants will either get the drink plus dietary advice, or just dietary advice alone. The g…

This phase 2 trial tests whether combining the immunotherapy drug tislelizumab with standard chemotherapy and a targeted chemo-blocking procedure (BACE) can shrink advanced, inoperable stage III non-small cell lung cancer enough to allow surgery. About 39 participants will receiv…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This phase 2 trial is testing a powerful combination of treatments for people with limited-stage small cell lung cancer (LS-SCLC) who have not had prior therapy. Participants will receive an immunotherapy drug (benmelstobart), an anti-angiogenic pill (anlotinib), standard chemoth…

This study tests a new treatment for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment before. It combines an immunotherapy drug (benmelstobart), a targeted therapy (anlotinib), and chemotherapy, followed by chest radiation. The goal is to see…

This study tests a device that uses both cold and radiofrequency to treat lung tumors during a standard bronchoscopy. Twenty people with early-stage lung cancer will receive the treatment before surgical removal of the tumor. The goal is to see if the device can safely and effect…

This early study tests a robotic bronchoscopy system that aims to detect, sample, and treat small lung tumors in a single procedure. About 30 adults with suspicious lung nodules up to 3 cm who cannot or choose not to have surgery will participate. The system uses advanced imaging…

This study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in people with extensive-stage small cell lung cancer whose cancer has already been treated. The goal is to see if the combination can shrink tumors. About 33 adults aged 18 to 75 with good perfor…

This Phase 2 trial tests two drug combinations for people with a specific genetic mutation (EGFR) in advanced non-small cell lung cancer. One group receives amivantamab plus lazertinib as first treatment; the other gets amivantamab plus chemotherapy after previous treatment stopp…

This phase II trial tests whether combining two drugs—sacituzumab tirumotecan and toripalimab—given before surgery can shrink tumors in people with stage II to IIIB non-small cell lung cancer (NSCLC). About 38 participants will receive the drugs intravenously over several weeks, …

This study tests whether adding capivasertib to osimertinib can help people with a specific type of advanced lung cancer whose disease has worsened after initial treatment. About 53 adults with EGFR-mutant NSCLC and additional PIK3CA/AKT1/PTEN gene changes will receive the two dr…

This phase 2 trial tests a sequence of targeted therapy (garsorasib), immunotherapy (ivonescimab), and chemotherapy before and after surgery for people with a specific type of lung cancer (KRAS G12C mutation) that can be removed. The goal is to see if this approach increases the …

This Phase 3 trial compares an experimental drug called SYS6010 with the standard chemotherapy docetaxel in about 506 people with advanced non-squamous non-small cell lung cancer that has not responded to prior treatments. The study aims to see if SYS6010 can slow cancer growth o…

This study compares two treatments for high-risk patients with early-stage non-small cell lung cancer: minimally invasive surgery (wedge resection) and stereotactic body radiation therapy (SBRT). The goal is to see which approach leads to longer disease-free survival and better q…

This phase 2 trial is testing whether a combination of the experimental drug QL1706, standard chemotherapy, and bevacizumab can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has specific gene changes and has stopped responding to targeted ther…

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced squamous non-small cell lung cancer live longer. About 108 people who have not had prior treatment will receive the combination. The study is not yet recr…

This study is testing a device called the HybridTherm® system, which uses freezing and radiofrequency heat to destroy small lung tumors during a routine bronchoscopy. The procedure is done before the patient's planned surgery to remove the tumor. The main goals are to see if the …

This study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in 30 people with extensive-stage small cell lung cancer whose disease got worse after initial chemotherapy plus immunotherapy. The goal is to see if the combo can shrink tumors or slow cancer gro…

This study tests a combination of two drugs, SHR-A1811 and pertuzumab, in people with advanced non-small cell lung cancer that has HER2 mutations or overexpression and has worsened after at least one prior treatment. The goal is to see if this combo can shrink tumors or slow dise…

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This early-phase trial is for people with non-small cell lung cancer that has stopped responding to second-line treatment. Researchers will use a lab test on a patient's own tumor cells to pick the best chemotherapy drugs, then add the statin pitavastatin. The goal is to see if t…

This study tests whether giving the anesthetic lidocaine during lung cancer surgery can reduce the chance of the cancer coming back. About 1,400 patients will be randomly assigned to receive lidocaine or a placebo. They will be followed for three years to track cancer recurrence …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This phase 2 trial tests the drug golidocitinib in 16 people with advanced lung cancer who have severe blood problems caused by immunotherapy. The goal is to see if the drug can safely improve blood counts and reduce symptoms. Participants take the drug until their blood levels r…

This study looks at people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. Some patients experience rapid tumor growth when treated with immunotherapy alone. The trial will test whether adding chemotherapy to the immunotherapy drug cemiplimab can pre…

This study looks at whether giving pembrolizumab infusions in the morning improves outcomes for people with metastatic non-small cell lung cancer. 58 participants will be randomly assigned to morning or standard scheduling. The goal is to see if timing affects how long the cancer…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This study tests a new drug combination (iparomlimab and tuvonralimab) plus chemotherapy as a first treatment for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this approach can shrink tumors or delay cancer growth. About 28 adults wi…

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This study tests whether a drug called ivonescimab can help prevent lung cancer from growing back after standard chemoradiation. It involves 63 adults with stage III non-small cell lung cancer that cannot be removed by surgery. Participants will receive ivonescimab infusions for …

This phase 3 trial tests whether adding Huaier granules (a traditional Chinese medicine) to microwave ablation improves outcomes for people with stage IA non-small cell lung cancer who cannot have surgery. 180 participants will be randomly assigned to receive ablation alone or ab…

This study tests whether taking two drugs—firmonertinib (a targeted pill) and bevacizumab (an infusion)—for three months before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). After surgery, patients may continue firmonertini…

This study looks at whether surgically removing the primary lung tumor before giving immunotherapy (sintilimab) and chemotherapy can improve outcomes for people with advanced non-small cell lung cancer that is not driven by EGFR or ALK mutations. About 118 participants will be ra…

This study looks at whether surgically removing the primary lung tumor before starting the targeted drug osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer. About 118 patients with stage III-IV cancer will be randomly assigned to get surgery plus osi…

This study tests a robotic bronchoscope to inject a dye near small lung nodules before they are removed surgically. The dye helps surgeons see the nodule during operation, making removal more accurate. Fifty patients with hard-to-find nodules will be enrolled, and researchers wil…

This study compares two types of surgery for people with a specific kind of lung cancer (adenocarcinoma) that is 2-3 cm in size and has a low-to-intermediate grade. One surgery removes just the part of the lung with the tumor (segmentectomy), while the other removes an entire lob…

This phase 3 trial tests QL2107, a biosimilar (copy) of the cancer drug Keytruda, in 122 adults with non-small cell lung cancer that has been surgically removed. The goal is to see if the body processes QL2107 the same way as Keytruda when given as an extra treatment after surger…

This study tests a drug called AK112 in 60 people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has specific genetic changes and has stopped responding to previous targeted therapy. The main goal is to see how many patients' tumors shr…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

Researchers are building an artificial intelligence system that analyzes chest CT images and offers decision support to doctors reading those scans for lung cancer. They use deidentified CT exams from routine care to develop and lock the AI models. In the prospective stage, about…

Researchers are testing a new PET/CT imaging tracer called [68Ga]-LY4257529 that targets a protein called GRPR, which some cancers make in large amounts. The study includes up to 60 adults with breast cancer or other tumors known or suspected to express GRPR, such as prostate, ov…

Radiation pneumonitis is a lung inflammation that can appear weeks after radiotherapy for lung cancer, and patients may not link their symptoms to the earlier treatment. Researchers developed a smartphone app called PneumoCheck for patients to use at home, hoping it helps detect …

Researchers at Penn State University are testing three software innovations designed to improve bronchoscopy guidance during lung cancer evaluations. The study enrolls a small number of adults who are already scheduled for a clinical bronchoscopy to examine abnormal lung tissue o…

Researchers are testing a new imaging agent called 111In-TJD-31 that targets placental alkaline phosphatase (ALPP), a protein found on many solid tumor cells but rarely in healthy adult tissue. The study enrolls 8 participants: 2 healthy volunteers who give blood samples and 6 pa…

Many cancer trials require patients to have specific molecular markers, so researchers test large numbers of people to find the few who qualify. This study evaluates FATHOM, an AI system that reads clinical trial records and routine tumor slides to predict which patients carry th…

Researchers are testing artificial intelligence models that analyze CT scans to find lung nodules and estimate whether they are benign or malignant. The study enrolls adults who have at least one non-calcified lung nodule measuring 3 to 30 mm. Participants receive no drugs or pro…

Researchers are testing whether an electronic nose that analyzes exhaled breath can serve as a noninvasive prescreening tool for several diseases at once. The study plans to enroll up to 20,000 adults and will first standardize the breath-sampling procedure, then evaluate how wel…

This trial tests whether a new imaging method, using femtosecond laser light and artificial intelligence, can accurately predict high-risk features in lung cancer, such as spread to lymph nodes. Researchers will compare the AI's predictions with actual pathology results from surg…

This trial tests whether adding a small probe called the Iriscope to standard bronchoscopy improves the diagnosis of lung nodules. Doctors usually guide the biopsy with real-time X-rays, but sometimes they cannot see the nodule directly. The Iriscope slides into the bronchoscope …

This trial tests whether a femtosecond laser imaging technique, combined with artificial intelligence, can accurately distinguish benign from malignant lung tissue in surgical specimens. Researchers will compare the AI-assisted diagnosis against standard pathology results. The st…

This trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …

This study explores whether a special MRI scan, done without any contrast dye, can tell the difference between benign and cancerous lung nodules that were flagged as suspicious on a routine lung cancer screening CT. Adults aged 50 to 80 with a history of heavy smoking and a Lung-…

This pilot study will offer low-dose CT scans to about 500 high-risk smokers aged 50-80 in Kuwait to see if this screening approach is practical and acceptable. The goal is to measure how many people agree to screening, identify barriers, and evaluate the use of AI to help read t…

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This pilot study explores whether a breath sample collected with the VosCryo device can provide enough cellular material to help diagnose advanced lung cancer. Researchers will compare breath samples from 12 people with late-stage lung cancer and 12 healthy relatives to see if th…

This study explores whether analyzing tumor DNA in cerebrospinal fluid can help doctors make better treatment decisions for people with malignant brain tumors or brain metastases from lung or breast cancer. Participants undergo a standard spinal tap or fluid collection, and the f…

This study tests whether an artificial intelligence (AI) model called Sybil can predict a person's risk of developing lung cancer based on a CT scan of the chest. The study enrolls people aged 18 to 80 who have a family history of lung cancer. Participants receive a CT scan, and …

This study tests an artificial intelligence (AI) prototype designed to quickly evaluate tissue samples taken during a bronchoscopy, a procedure used to diagnose lung cancer. The AI analyzes microscope images of the samples to determine if they are adequate for diagnosis and wheth…

This early-phase trial will test a new radioactive tracer called [68Ga]Ga-PentixaFor in 15 people with metastatic small cell lung cancer. The goal is to see if this PET-CT scan can find tumors as well as the standard FDG PET-CT scan, both at diagnosis and when the disease gets wo…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study is testing whether a blood test that looks for genetic changes (ctDNA) can help detect lung cancer early in people who have suspicious lung nodules found on CT scans. Researchers will collect blood samples from 200 participants in Hong Kong and Vietnam at the start and…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study will check if low-dose CT scans can find lung cancer early in 1,716 high-risk smokers in India. Participants get a baseline scan, and if anything looks suspicious, they are referred to a team of specialists for follow-up. The goal is to see if this screening method wor…

This study will test a new, disposable freezing catheter (Celsio) in 30 people who need a lung procedure. The catheter uses extreme cold to help diagnose or treat conditions like lung cancer and interstitial lung disease. Unlike current devices, it does not need a bulky console o…

This study will enroll 2,000 people aged 50 or older in Mexico, Costa Rica, Colombia, and Argentina who are at high risk for lung cancer due to smoking, wood smoke exposure, family history, or COPD. Participants will get a chest X-ray analyzed by artificial intelligence and a low…

This study tests whether a special dye, given before a bronchoscopy, can make lung tumors glow so doctors can see them more clearly. About 20 adults with a suspicious lung nodule or lymph node will receive the dye and then have a bronchoscopy with a special camera. The goal is to…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This study aims to see if a blood test, taken before lung cancer surgery, can predict which patients will develop serious lung complications afterward. Researchers will analyze immune cells and proteins in the blood of 100 adults undergoing lung surgery. If the test works, it cou…

This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…

This study compares 3D models from non-contrast CT scans to standard contrast CT scans for planning minimally invasive lung cancer surgery. Researchers will check if the 3D models accurately show blood vessels, airways, and tumor location during surgery. If they work, patients mi…

This study will test whether a special CT scan (dual-energy CT) can be as good as MRI for mapping tumors and healthy organs before radiation therapy. Researchers will enroll 80 people with brain, bone, head/neck, or lung cancer. If DECT works well, it could save time and money co…

Researchers at Johns Hopkins University are testing whether a short animated video and brochure, sometimes followed by a phone call, can help people at higher risk of lung cancer get low-dose CT screening. The trial enrolls adults aged 50 to 80 with a significant smoking history …

This trial tests whether a community-based program called Witness Project Lung can increase lung cancer screening among Black adults aged 50 to 80 who smoke or quit within the past 15 years. The program uses peer role models, videos, and tailored materials to educate participants…

This study tests a vaccine called SurVaxM in 80 current or former heavy smokers at high risk for lung cancer. The vaccine trains the immune system to recognize and attack cells that produce a protein called survivin, which is common in cancer cells. The goal is to see if the vacc…

This study compares two ways to share lung cancer screening information with people who call tobacco quitlines. Participants are quitline clients aged 50 to 80 with a heavy smoking history. One approach offers extra coaching and navigation support. The goal is to see which method…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether electroacupuncture (using mild electric pulses on needles) plus tiny thumbtack needles can prevent nerve damage caused by chemotherapy in people with early-stage cancer. About 278 patients with breast, stomach, bowel, lung, or ovarian cancer will receive …

This study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…

This study aims to find the best ways to increase lung cancer screening among current and former smokers aged 50-80 in community health centers. About 19,000 participants will receive text messages and clinic support to complete eligibility checks and low-dose CT scans. The goal …

This study tests whether the blood thinner apixaban can prevent dangerous blood clots in people with lung cancer who are receiving chemotherapy or similar treatments. About 1,456 participants will take either apixaban or a placebo twice a day for six months. The goal is to see if…

Researchers at Hospital Universitario Austral in Argentina are testing whether a structured three-session music therapy program called MUSPAL360 can be delivered to hospitalized adults with advanced cancer receiving palliative care. The program combines live music therapy with 36…

Researchers are testing an experimental drug called GMDTC in adults with solid tumors who have mild kidney problems caused by cisplatin chemotherapy. The trial aims to find out if GMDTC is safe, what side effects it causes, and how the body processes it. Participants receive cisp…

This early-stage trial tests whether the drug ponsegromab can help adults with advanced non-small cell lung cancer who are losing muscle mass (cachexia). About 80 participants will receive either ponsegromab or a placebo. The study measures changes in muscle size and physical fun…

This pilot trial tests whether psilocybin-assisted therapy can help adults with advanced cancer who feel demoralized, hopeless, or distressed about their illness. Participants receive a single dose of psilocybin (either 25 mg or 5 mg) during a group session, paired with either mi…

This trial tests whether low-frequency repetitive transcranial magnetic stimulation (rTMS) can improve sleep quality in adults undergoing surgery for lung cancer. Participants with poor sleep before surgery will receive either active rTMS or a sham (inactive) treatment over five …

This study tests a program called Dyadic Life Review, where older adults with advanced cancer and memory problems talk through their life stories with a caregiver. The goal is to see if these conversations reduce caregiver burden and stress while bringing the pair closer together…

This trial tests whether low-frequency repetitive transcranial magnetic stimulation (rTMS) can improve sleep quality in adults with advanced non-small cell lung cancer who have trouble sleeping during hospital stays. Researchers will randomly assign 160 participants to receive ei…

This study aims to create a brief behavioral intervention for older adults (60+) with lung cancer, addressing aging-specific concerns like depression, anxiety, pain, and shortness of breath. In the first phase, patients, caregivers, and providers give feedback on the program. In …

This study tests if giving a long-lasting numbing medicine in two different places around the ribs and chest wall can reduce pain and the need for strong painkillers after robotic lung surgery. About 300 adults having this surgery will be randomly assigned to receive the numbing …

This trial tests whether adding mindfulness training to a standard respiratory symptom management program can reduce anxiety and ease breathlessness, cough, and fatigue in people with lung cancer. About 189 patients will be randomly assigned to one of three groups: the combined m…

This pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…

This randomized trial tests whether immersive virtual reality (VR) can reduce anxiety in people with lung cancer during immunotherapy or chemo-immunotherapy infusions. Half of the 60 participants will use a VR headset showing calming nature scenes during four infusion visits, whi…

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…

Shortness of breath, or dyspnea, affects most lung cancer patients and often persists despite standard treatments. This pilot study tests a stepped-care behavioral intervention called INSPIRE, which starts with brief coping skills and adds more intensive psychological support onl…

This trial tests whether a digital platform that sends symptom check-ins and self-care tips via text message can help people with head and neck or lung cancer report their health more consistently. Participants either receive standard symptom questionnaires or get extra monitorin…

This study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…

This study tests whether giving a nerve block at two rib levels instead of one can better control pain after video-assisted thoracoscopic surgery for lung cancer. Eighty-eight adults scheduled for lung surgery will receive either a standard single-point block or a two-point block…

This study tests a short behavioral program called BREEZE+ to help people with advanced lung cancer manage breathlessness. The program includes three nurse-led sessions and a digital app that teaches breathing and relaxation skills. Researchers will compare this to usual care in …

This trial compares standard radiation therapy with a new method that specifically avoids damaging small airways in the lungs. The goal is to see if this airway-sparing approach helps patients with stage III non-small cell lung cancer retain better breathing function after treatm…

This pilot study tests whether using bright light therapy for an hour each morning, delivered through an iPad app, is tolerable for people with advanced melanoma or non-small cell lung cancer who are about to start immunotherapy. The idea is that synchronizing the body's internal…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This study tests a smart breathing exercise device for people recovering from lung cancer surgery. About 200 adults will either use the device for 30 days after surgery or receive standard care. The goal is to see if the device improves lung function, reduces shortness of breath,…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests a home-based app for lung cancer patients on combination drug therapy. The app helps patients track symptoms, get personalized advice, and receive nurse support during treatment breaks. Researchers will see if it reduces symptom burden and improves quality of lif…

This study tests whether a smartphone reminder app can help lung cancer patients stay physically active during radiation therapy. About 32 adults with lung cancer will use the app or standard care, and their daily step counts will be compared. The goal is to see if simple digital…

This study tests whether a 12-week exercise program, delivered via Zoom, is practical and helpful for older adults (65+) with cancer who live in rural areas. Participants will do two supervised exercise sessions per week. The goal is to see if the program improves quality of life…

This study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…

This study tests a new program called ADAPT, which is a type of talk therapy for lung cancer patients and their spouses. The goal is to help both partners feel less afraid of the cancer coming back. About 72 couples will try the program during chemotherapy or radiation and answer…

This study tests whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help advanced cancer patients who are losing weight and appetite—a condition called cachexia. About 66 adults with stomach, colorectal, or lung cancer will receive the treatment. Th…

This study tests whether a supervised exercise program, started two weeks before chemotherapy and continued for 16 weeks during treatment, can help adults aged 35 to 65 with breast, lung, or colon cancer tolerate chemotherapy better. The goal is to see if participants can receive…

This study tests whether a supervised exercise program, done alongside chemotherapy or immunotherapy, can improve fitness and recovery in patients with locally advanced non-small cell lung cancer. 74 participants will be randomly assigned to either exercise training or usual care…

This study tests a special care plan to help Chinese patients with advanced EGFR-mutated lung cancer who are taking the drug amivantamab. The plan focuses on preventing common side effects like blood clots, skin rashes, and infusion reactions. About 122 adults will join to see if…

This study looks at whether a two-week program of walking and breathing exercises before surgery for non-small cell lung cancer can help reduce pain, speed up recovery, shorten hospital stays, and improve quality of life. About 62 adults scheduled for surgery will be split into t…

This study compares a newer anesthesia method where patients breathe on their own during lung surgery to the standard method using a breathing tube and machine. About 1,600 people having minimally invasive lung nodule removal will be randomly assigned to one of the two methods. T…

This early study tests whether selpercatinib, a drug already used for certain cancers, can help with cachexia (severe weight loss and appetite loss) in people with advanced lung, colon, or pancreatic cancer. Seven participants will take the drug twice daily for 12 weeks, with reg…

This study tests whether using a lung perfusion PET/CT scan to guide radiation planning can reduce lung injury compared to standard anatomical planning. About 418 adults with lung tumors receiving stereotactic body radiotherapy (SBRT) will be randomly assigned to one of the two p…

This study tests whether listening to a hypnotic audio recording during a 4D CT scan can reduce image artifacts (blurring or distortions) for 25 adults receiving lung cancer radiation therapy. Participants will have scans with and without the recording to compare quality. The goa…

This study tests whether a short, intensive psychological program before lung cancer surgery can lower anxiety and depression. About 138 adults scheduled for lung cancer surgery will be split into three groups: one receiving four weekly therapy sessions, one refusing support, and…

This study compares different anesthesia methods to see if they can prevent chronic cough after video-assisted lung surgery. 228 lung cancer patients will be randomly assigned to different airway management strategies during surgery. Researchers will track cough severity, duratio…

This study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…

Researchers are testing whether people with non-small cell lung cancer can collect their own small blood samples at home using a finger-prick kit. Participants receive standard treatment with docetaxel, paclitaxel, alectinib, or lorlatinib, and the samples measure how much cancer…

This study explores whether artificial intelligence can help perform high-field whole-body MRI scans faster while keeping image quality high. Researchers will compare standard MRI sequences with AI-accelerated versions in 600 adults undergoing screening for prostate, lung, or vas…

This study looks at how much pembrolizumab (an immunotherapy drug) remains in the blood after treatment ends and whether that affects how well chemotherapy works later. Researchers will follow 110 people with non-small cell lung cancer or head and neck cancer who have stopped pem…

Researchers are studying whether the mix of bacteria in a person's gut can predict how well they respond to immunotherapy drugs called immune checkpoint inhibitors. The trial enrolls about 360 adults with advanced non-small cell lung cancer, melanoma, endometrial cancer, or cervi…

This study will screen 477 current or former smokers in Brazil for lung cancer using CT scans. It aims to see how often the scans give false alarms (false positives) in a region where lung infections are common. The goal is to improve screening accuracy and reduce unnecessary fol…

Researchers are testing an experimental cryoablation catheter that freezes lung tissue, using donated human lungs kept alive outside the body. The goal is to see whether the device can reach and cool tumors through the airways, which could offer a less invasive option than surger…

Some people who have keyhole lung cancer surgery develop lasting breathlessness and struggle with gentle exercise, even if their breathing was fine before. Researchers suspect the right side of the heart, which pumps blood to the lungs, may be weakened by the extra pressure it fa…

This study will enroll 1,500 current or former smokers aged 50-80 to see if an artificial intelligence (AI) model can help doctors better detect lung nodules and predict cancer spread. Participants will undergo CT scans, and the AI's results will be compared to standard radiologi…

This observational study aims to understand how symptoms like pain, fatigue, and nausea change over time in children with advanced cancer. Researchers will ask children aged 8 to 18 and their caregivers to complete surveys about symptoms and overall health. The goal is to identif…

Researchers are collecting blood and tumor tissue samples from 30 adults with relapsed small-cell lung cancer who are receiving a standard DLL3 T cell engager therapy. The goal is to track changes in tumor markers over time and see if those changes relate to how well the treatmen…

This study reviews medical records of 250 people with advanced or metastatic non-small cell lung cancer that has a specific change in the EGFR gene. Researchers want to learn about patients' backgrounds, the treatments they receive, and how well those treatments work. The goal is…

This observational study follows Indian adults with resectable non-small cell lung cancer who are prescribed durvalumab as part of their routine care. The goal is to monitor how often patients experience serious side effects, including severe adverse events and other complication…

This study is exploring whether the bacteria in your gut can predict how well a certain type of lung cancer responds to treatment. Researchers are following 100 people with stage II-IIIB non-small cell lung cancer who are receiving chemoimmunotherapy before surgery. The goal is t…

This study is looking at whether analyzing blood, urine, and stool samples can help predict which lung cancer patients are more likely to develop radiation pneumonitis—a type of lung inflammation—after receiving immunotherapy and radiation therapy. The researchers will collect sa…

This study aims to better understand tuberculosis (TB) across its entire spectrum—from early, symptom-free infection to active disease and after treatment. Researchers will recruit TB patients and their close contacts to analyze immune responses and identify biomarkers that could…

This trial tests a new communication workflow called CORRECT that helps radiologists and radiation oncologists work together more effectively when planning radiation therapy for lung and head-and-neck cancers. About 194 patients will be involved, and doctors will use a shared sys…

This study surveys people with lung tumors before and after a procedure called percutaneous ablation, which uses heat or cold to destroy cancer cells. Participants will rate symptoms like pain, fatigue, and shortness of breath on a simple scale. The goal is to understand how pati…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study tests a new way to see where an immunotherapy drug goes in the lungs of people with stage III lung cancer. Twenty participants will receive a small dose of a fluorescent version of the drug durvalumab, then have a special camera bronchoscopy to spot the drug in tumors …

This study takes leftover tumor samples from people with EGFR-mutant non-small cell lung cancer and grows them in the lab as cell cultures and organoids. Researchers will test different anti-EGFR drugs on these models to see which ones work best for each type of mutation and expl…

This study looks at how certain cancers develop in people with HIV and what factors might increase their risk. Researchers will analyze medical data from 1,000 HIV-positive adults to track which types of cancer occur most often and why. The goal is to improve early detection and …

This study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This trial tests whether using a personalized 3D lung model during preoperative consultations helps patients better understand their lung surgery options and feel more involved in decision-making. Adults scheduled for thoracoscopic lung resection for suspected or confirmed lung t…

This phase 1 trial investigates how HS-10504, an experimental drug for EGFR-mutant non-small cell lung cancer, changes the way the body processes midazolam, a common sedative. About 24 patients with advanced lung cancer who have stopped responding to standard EGFR-targeted therap…

This study is testing whether a blood test can locate where colorectal cancer has returned or spread after surgery. Researchers are analyzing genetic markers in the blood to build a model that predicts whether a recurrence is local or distant. The goal is to improve early detecti…

This study uses blood tests (liquid biopsies) to track how small cell lung cancer changes during chemotherapy and immunotherapy. Researchers will analyze DNA from blood samples taken before, during, and after treatment in 50 patients. The goal is to understand why some cancers be…

This study explores whether a hair follicle or cheek swab can accurately measure a person's internal body clock (circadian rhythm) in patients with advanced lung cancer receiving immunotherapy. Researchers will use a new tool called TimeTeller to analyze gene activity from these …

This study will enroll over 3,200 adults in Delhi and surrounding areas to understand how air pollution, especially fine particles (PM2.5), combines with other factors like smoking and genetics to increase lung cancer risk. Researchers will also look for biomarkers and identify g…

This study will develop an artificial intelligence model that uses a patient's series of CT scans over time to predict whether a lung nodule will grow or become cancerous. Researchers will analyze scans from nearly 5,000 people to train the AI to recognize different growth patter…

This observational study looks at adults with non-small cell lung cancer that has spread to the brain. Researchers want to see if getting radiation and immunotherapy 30 days apart or closer together changes how long the brain tumors stay stable and how long patients live. Partici…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study looks at two different methods doctors use to re-inflate a lung after it has been collapsed during surgery. About 350 people having lung surgery will take part. The goal is to see which method leads to fewer lung problems like pneumonia or collapsed air sacs in the wee…

This study looks at a specific type of lung cancer called lung adenocarcinoma and how it can spread through tiny air spaces in the lungs. Researchers will collect tumor and healthy tissue samples from 140 patients to find genetic markers that might predict this spread. The goal i…

This study looks at medical records of 3,000 adults with lung cancer to see if the stage at diagnosis is shifting to earlier, more curable stages. Researchers will track how often cancer is found through screening programs, chest X-rays, or heart scans. No new treatments or tests…

This study tests whether a specially designed educational toolkit, called the Lung Toolkit, can improve knowledge about lung cancer and screening among American Indian and Alaskan Native adults aged 50 to 80 who smoke cigarettes. The toolkit includes a website with resources and …

This study aims to find better ways to help Veterans quit smoking when they come in for lung cancer screening. Since smoking causes most lung cancers, combining screening with stop-smoking support could save more lives. The project will test new processes at a few VA sites and me…

This study aims to see how nicotine changes eye movements in people who use e-cigarettes. Researchers will measure things like how fast eyes move and how well they follow objects, along with blood nicotine levels and self-reported feelings. The goal is to find a more objective wa…

This study watches how well the drug repotrectinib works and what side effects it causes in Korean patients with a specific type of lung cancer or solid tumors that have certain gene changes. About 10 patients will be followed for up to 12 months during their normal treatment. Th…

This study compares a new electromagnetic navigation system to standard CT scans for guiding surgeons to small lung nodules during surgery. About 400 adults with nodules up to 2 cm will be randomly assigned to one method. The goal is to see which approach helps surgeons find and …

This study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …

This study will look back at medical records of 300 people with advanced non-small cell lung cancer (NSCLC) whose disease got worse after first-line immunotherapy. Researchers want to see which second-line treatments were used and how well they worked in real-world practice. The …

This study looks at whether people with peripheral vascular disease (narrowed leg arteries) might also be at high risk for lung cancer because of shared smoking history. Researchers will check if these patients qualify for lung cancer screening and refer them for a low-dose CT sc…

This study tests whether a special headset (extended reality) can help surgeons plan the removal of cancer-affected lymph nodes in the neck for people with lung cancer. Ten patients will have their PET and CT scans combined into a 3D model that the surgeon views just before surge…

This study looks at how adults with lung nodules that might be cancer make decisions about their care before a final diagnosis. Researchers will use questionnaires to measure patients' confidence, doubts, and satisfaction with their choices. The goal is to find out what factors h…

This study looks at how different surgical tools used during lung cancer surgery might affect coughing after the operation. About 248 adults having right lung surgery will be randomly assigned to one of two tool types. The goal is to find out which tool causes less nerve damage a…

This study tests whether the Apple Vision Pro headset can help surgeons see blood vessels more clearly during lung surgery. Twenty adults scheduled for lung surgery will have a CT scan before the operation, and the surgeon will wear the headset to view 3D images during the proced…

This study collects blood and tissue samples from 110 adults with advanced lung, head and neck, or mesothelioma cancer. The samples are stored in a biobank to help scientists study cancer genes and find better ways to predict treatment outcomes. Participants do not receive any ex…

This early-stage study looks at how the drug anecatibin fumarate is processed in the body of people with and without liver problems. It will include 24 adults with lung cancer. The goal is to understand safety and drug levels, not to test if the drug works.

This study will expose 24 healthy adults to different levels of wildfire smoke in a safe, controlled room to see how it affects their lungs and brain. Researchers want to understand why some people may be more vulnerable to long-term lung diseases like asthma, COPD, and lung canc…

This study will collect tumor samples and medical data from 150 adults with non-small cell lung cancer (stages I to IV) at Bordeaux University Hospital. Researchers will analyze the molecular, metabolic, and immune features of the tumors to understand how the cancer progresses an…

This study will test if a simple, low-intensity cycling exercise combined with a handheld monitor can predict serious complications in lung cancer patients before surgery or other treatments. Researchers will include 500 adults with suspected lung cancer. The goal is to make risk…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study looks at sputum and blood samples from 50 adults with advanced non-small cell lung cancer who are starting immunotherapy. Researchers want to find immune cell changes that could predict which patients will respond well to treatment. The goal is to better understand the…

This study looks at whether an extra cleaning step during a common lung cancer staging procedure (EBUS) can reduce contamination of tissue samples. Researchers will collect samples from 204 adults with suspected lung cancer. The goal is to see if better cleaning leads to more acc…

This study will enroll 63 people with advanced non-small cell lung cancer whose disease has been stable for at least 6 months. Participants will take part in a 3-month rehabilitation program that includes physical activity. Researchers will measure quality of life, hand grip stre…

This study looks at how cancer and its treatments change the way people experience food, including taste, mouth health, and overall eating pleasure. Researchers will ask 180 adults with different cancers to fill out a detailed questionnaire about their eating habits and feelings.…

This study looks back at medical records of 350 people with advanced non-small cell or small cell lung cancer who took anlotinib after their previous treatment stopped working. The goal is to see how well anlotinib works and how safe it is when used in later lines of therapy. The…

This study looks at whether tiny particles in the blood, called extracellular vesicles, can help doctors predict if immunotherapy will work for people with advanced lung cancer or melanoma. Researchers will collect blood samples from 378 patients before and during standard treatm…

This study looks at how a personalized strength training program affects people with different cancers, including lung, colon, breast, and blood cancers. 150 adults will either do supervised strength training plus home exercises, or just home exercises, for 12 weeks. Researchers …

This study will analyze genetic data from 100,000 people to see if variations in aldehyde-metabolizing genes (ADH1B and ALDH family) are linked to lung cancer risk, especially in people who have never smoked. The goal is to understand how these genes might influence the developme…

This study looks at whether a blood test for circulating tumor DNA (ctDNA) can detect leftover cancer after surgery in people with breast, lung, prostate, ovarian, or stomach cancer. About 840 participants will give blood samples before and after standard treatments. No new treat…

This study watches for thinking and memory issues in 90 adults with early-stage, operable lung cancer. Researchers will track complaints like forgetfulness or trouble focusing before, during, and after treatment using simple questionnaires. The goal is to understand when these pr…

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study will collect blood samples from 620 adults with cancer (including lung cancer) to look for tiny markers released by tumors. Researchers want to see if these markers can help predict how well treatments work or when the cancer might come back. The study does not test a …

This observational study aims to understand how the immune system and tumor markers relate to treatment response in 500 people with advanced non-small cell lung cancer. Participants will provide tumor samples before and during immunochemotherapy. The study does not test any new d…

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…